XML 24 R14.htm IDEA: XBRL DOCUMENT

Balance Sheet Details

9 Months Ended

Sep. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

5. Balance Sheet Details

Inventory consisted of the following (in thousands):


	September 30, 2023		December 31, 2022
Finished goods	$	4,927	$	1,926
Work in process		4,209		4,427
Raw material		16,260		5,207
	$	25,396	$	11,560
Reported as:
Inventory	$	20,768	$	6,636
Long-term inventory		4,628		4,924
Total	$	25,396	$	11,560

Amount reported as long-term inventory consisted of raw materials for NUPLAZID as of September 30, 2023 and December 31, 2022. The Company has raw materials beyond a one year production plan that help limit the exposures from potential supply interruption. Those raw materials beyond the one year production plan were classified as long-term inventory.

Accrued liabilities consisted of the following (in thousands):


	September 30, 2023		December 31, 2022
Accrued sales allowances	$	66,358	$	26,046
Accrued compensation and benefits		34,160		28,023
Accrued contingent payments		29,583		—
Accrued research and development services		25,304		35,048
Accrued consulting and professional fees		15,457		11,377
Current portion of lease liabilities		9,031		9,305
Accrued taxes		8,452		377
Other		8,948		2,708
	$	197,293	$	112,884